AI-Driven Pharmacogenomics and Precision Medicine: Future of Personalized Therapy
Pharmacogenomics and artificial intelligence (AI) are emerging as important drivers of precision medicine, enabling healthcare systems to adopt individualized therapeutic approaches. Pharmacogenomics examines how genetic variations influence drug response, efficacy, metabolism, and toxicity, while AI provides advanced computational tools for analyzing complex genomic and clinical data. This review highlights the integration of AI-driven pharmacogenomics in personalized therapy and its potential to improve treatment outcomes. Machine learning, deep learning, natural language processing, and big data analytics are increasingly used to identify genetic variants, predict drug responses, optimize medication selection and dosage, and reduce adverse drug reactions. These technologies support the interpretation of large-scale genomic information and facilitate evidence-based clinical decision-making. Significant applications have been demonstrated in oncology, cardiovascular diseases, neurological and psychiatric disorders, and rare genetic diseases, where personalized treatments can enhance therapeutic efficacy and patient safety. Recent advances in genomic sequencing, multi-omics integration, digital health technologies, explainable AI, and real-time patient monitoring have further expanded the scope of precision medicine. However, challenges related to data privacy, algorithm bias, regulatory frameworks, and clinical implementation remain. Future developments in explainable AI, predictive analytics, and AI-powered personalized therapy are expected to improve treatment precision and accelerate the realization of truly individualized healthcare. Overall, the convergence of AI and pharmacogenomics represents a transformative approach to modern medicine with substantial potential to improve patient outcomes and optimize therapeutic interventions.